top of page

NEXT-GENERATION IN-VITRO DIAGNOSTICS

We strive towards improving the quality of life of patients by developing in-vitro diagnostic tests for early and non-invasive detection and monitoring of cancer.

  • LinkedIn
Workplaces

PROBAN - REVOLUTIONIZING PROSTATE CANCER SCREENING 

ONTRACK Biomedical has developed an innovative method to generate monoclonal antibodies for in-vitro diagnostics. PROBAN is a urine test for the early detection of prostate cancer. Patients with elevated levels of PSA can perform our urine test to decide whether to perform a prostate biopsy.

60

patented urinary biomarkers for the diagnosis of prostate cancer

50%

reduction of prostate biopsies performed on men who have  no prostate cancer

1.5 M

CHF in competitive grants raised for the academic R&D of PROBAN

40 M

men could benefit from PROBAN every year

HIGHLY-SENSITIVE, NON-INVASIVE DIAGNOSTICS

INNOVATIVE
IMMUNOASSAYS

ONtrack Biomedical's core technology is an innovative and efficient method to develop highly-sensitive and highly-specific immunoassays quickly and cost-effectively

HIGH SENSITIVITY FOR PROSTATE CANCER

PROBAN has a negligible number of false negatives, meaning that only patients without prostate cancer result negative to our urine test

QUALITY OF LIFE

Thanks to a simple urine test, we will reduce to a half the number of men who will perform a prostate biopsy if they do not have a prostate tumor

NOVEL BIOMARKERS

ONtrack Biomedical AG has developed an innovative strategy to identify and validate novel and non-invasive biomarkers, applicable to any disease

GET IN TOUCH

ONTRACK Biomedical AG
c/o USZ (Universitätsspital Zurich)
Klinik für Urologie (4th Floor)

Wagistrasse 21

8952 Schlieren

contact@ontrackbiomedical.com

  • Linkedin

Thanks for submitting!

bottom of page